APA (7th ed.) Citation

Alexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, Vardhaman Patel, Hanke Zheng, Laetitia N'Dri, . . . Gordon Lam. (2024). Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. Becaris Publishing Limited.

Chicago Style (17th ed.) Citation

Alexandrina Balanean, et al. Real-world Clinical Outcomes and Rationale for Initiating Abatacept as a First-line Biologic for Patients with Anticitrullinated Protein Antibody- and Rheumatoid Factor-positive Rheumatoid Arthritis. Becaris Publishing Limited, 2024.

MLA (9th ed.) Citation

Alexandrina Balanean, et al. Real-world Clinical Outcomes and Rationale for Initiating Abatacept as a First-line Biologic for Patients with Anticitrullinated Protein Antibody- and Rheumatoid Factor-positive Rheumatoid Arthritis. Becaris Publishing Limited, 2024.